Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further expansion of (pre-)malignant cells1,2. Key signalling components of the senescence machinery, such as p16INK4a, p21CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as critical regulators of stem-cell functions (which are collectively termed ‘stemness’)3. In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stem-cell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cell-autonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions

Gene Expression Omnibus


  1. 1.

    & Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014)

  2. 2.

    , & Inside and out: the activities of senescence in cancer. Nat. Rev. Cancer 14, 547–558 (2014)

  3. 3.

    Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 453, 306–313 (2008)

  4. 4.

    et al. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb. Symp. Quant. Biol. 73, 513–522 (2008)

  5. 5.

    , , , & Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997)

  6. 6.

    et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005)

  7. 7.

    et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005)

  8. 8.

    . et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002)

  9. 9.

    et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501, 421–425 (2013)

  10. 10.

    et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598–602 (2012)

  11. 11.

    & Stem cells: The promises and perils of p53. Nature 460, 1085–1086 (2009)

  12. 12.

    et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593–599 (2000)

  13. 13.

    et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703–716 (2003)

  14. 14.

    et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat. Genet. 45, 34–42 (2013)

  15. 15.

    et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 354, aaf4445 (2016)

  16. 16.

    et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 31, 172–183 (2017)

  17. 17.

    et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2, 333–344 (2008)

  18. 18.

    et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409–414 (2003)

  19. 19.

    et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650–1653 (2010)

  20. 20.

    . et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008–3019 (1998)

  21. 21.

    , , , & Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007)

  22. 22.

    et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950–7955 (2011)

  23. 23.

    . et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24, 1389–1402 (2010)

  24. 24.

    et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011)

  25. 25.

    et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990 (2013)

  26. 26.

    et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016)

  27. 27.

    et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132–147.e16 (2017)

  28. 28.

    et al. Wnt signaling potentiates nevogenesis. Proc. Natl Acad. Sci. USA 110, 16009–16014 (2013)

  29. 29.

    et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br. J. Cancer 103, 505–509 (2010)

  30. 30.

    et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985)

  31. 31.

    et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323–337 (2001)

  32. 32.

    ., . & Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006)

  33. 33.

    et al. Tumor stroma-derived TGF-β limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17, 262–272 (2010)

  34. 34.

    . et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289–298 (2002)

  35. 35.

    et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145–158 (2011)

  36. 36.

    , , , & . INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670–2677 (1999)

  37. 37.

    , , , & Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251, 70–72 (1991)

  38. 38.

    , & Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029–1035 (2000)

  39. 39.

    , , & Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752–757 (1997)

  40. 40.

    et al. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 25, 2137–2146 (2011)

  41. 41.

    et al. Wnt5a is required for endothelial differentiation of embryonic stem cells and vascularization via pathways involving both Wnt/β-catenin and protein kinase Cα. Circ. Res. 104, 372–379 (2009)

  42. 42.

    et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289–1295 (2005)

  43. 43.

    . et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62–73 (2008)

  44. 44.

    et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995)

  45. 45.

    et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 110, 2996–3004 (2007)

  46. 46.

    , , , & Flow cytometry in cancer stem cell analysis and separation. Cytometry A 81A, 284–293 (2012)

  47. 47.

    et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659 (2009)

  48. 48.

    et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl Acad. Sci. USA 108, 13253–13257 (2011)

  49. 49.

    et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313–324 (2010)

  50. 50.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)

  51. 51.

    , & Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protocols 2, 1896–1906 (2007)

  52. 52.

    , , , & Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protocols 4, 484–494 (2009)

  53. 53.

    & MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008)

  54. 54.

    , & Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protocols 1, 729–748 (2006)

  55. 55.

    . & ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70–78 (2009)

  56. 56.

    et al. A stem cell molecular signature. Science 298, 601–604 (2002)

  57. 57.

    , , & The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010)

  58. 58.

    et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977–2000 (2002)

  59. 59.

    et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006)

  60. 60.

    et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 1, 578–591 (2007)

Download references


We thank G. Evan, the late A. Harris, T. Jacks and T. Jenuwein for mice, cells and materials; E. Berg, N. Burbach, A. Herrmann, H. Lammert, S. Mende, B. Teichmann and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) flow cytometry laboratory for technical assistance; and members of the Schmitt laboratory for discussions and editorial advice. This work was supported by a Ph.D. fellowship to J.R.D. from the Boehringer Ingelheim Foundation; by grants from the Deutsche Forschungsgemeinschaft to B.D., M.H. and C.A.S. (SFB/TRR 54) and to A.T. (SFB 873); by the Helmholtz Alliance ‘Preclinical Comprehensive Cancer Center’ grant (HA-305) from the Helmholtz Association to A.T. and C.A.S.; by the Dietmar Hopp Foundation to A.T.; and by the Deutsche Krebshilfe (grant 110678) to C.A.S. This interdisciplinary work was further made possible by the Berlin School of Integrative Oncology (BSIO) graduate program funded within the German Excellence Initiative, and the German Cancer Consortium (GCC).

Author information


  1. Charité – Universitätsmedizin Berlin, Medical Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum – MKFZ, Virchow Campus, 13353 Berlin, Germany

    • Maja Milanovic
    • , Dorothy N. Y. Fan
    • , Dimitri Belenki
    • , J. Henry M. Däbritz
    • , Jan R. Dörr
    • , Marlen Metzner
    • , Katharina Pardon
    • , Maurice Reimann
    • , Bernd Dörken
    • , Soyoung Lee
    •  & Clemens A. Schmitt
  2. Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), 69120 Heidelberg, Germany

    • Dorothy N. Y. Fan
    • , Andreas Trumpp
    • , Bernd Dörken
    • , Michael Hummel
    • , Soyoung Lee
    •  & Clemens A. Schmitt
  3. German Cancer Research Center (Deutsches Krebsforschungszentrum – DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

    • Dorothy N. Y. Fan
    •  & Andreas Trumpp
  4. Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner site Berlin, Berlin, Germany

    • Dorothy N. Y. Fan
    • , Andreas Trumpp
    • , Bernd Dörken
    • , Michael Hummel
    • , Soyoung Lee
    •  & Clemens A. Schmitt
  5. Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA

    • Zhen Zhao
  6. Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125 Berlin, Germany

    • Yong Yu
    • , Tamara Kanashova
    • , Bernd Dörken
    • , Gunnar Dittmar
    • , Soyoung Lee
    •  & Clemens A. Schmitt
  7. Charité – Universitätsmedizin Berlin, Department of Pathology, Berlin, Germany

    • Lora Dimitrova
    • , Dido Lenze
    •  & Michael Hummel
  8. Institute of Molecular Pathology (IMP), Vienna Biocenter, Dr Bohr-Gasse 7, 1030 Vienna, Austria

    • Ines A. Monteiro Barbosa
    •  & Johannes Zuber
  9. Equipe Labellisée Ligue Contre le Cancer, Department of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, UMR7104, Institut National de la Santé et de la Recherche Médicale, U964, Université de Strasbourg, 67400 Illkirch, France

    • Marco A. Mendoza-Parra
    •  & Hinrich Gronemeyer
  10. Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

    • Andreas Trumpp
  11. Berlin Institute of Health, Anna-Louisa-Karsch-Straße 2, 10178 Berlin, Germany

    • Bernd Dörken
    • , Michael Hummel
    •  & Clemens A. Schmitt
  12. Luxembourg Institute of Health, 1A-B rue Thomas Edison, L-1455 Strassen, Luxembourg

    • Gunnar Dittmar


  1. Search for Maja Milanovic in:

  2. Search for Dorothy N. Y. Fan in:

  3. Search for Dimitri Belenki in:

  4. Search for J. Henry M. Däbritz in:

  5. Search for Zhen Zhao in:

  6. Search for Yong Yu in:

  7. Search for Jan R. Dörr in:

  8. Search for Lora Dimitrova in:

  9. Search for Dido Lenze in:

  10. Search for Ines A. Monteiro Barbosa in:

  11. Search for Marco A. Mendoza-Parra in:

  12. Search for Tamara Kanashova in:

  13. Search for Marlen Metzner in:

  14. Search for Katharina Pardon in:

  15. Search for Maurice Reimann in:

  16. Search for Andreas Trumpp in:

  17. Search for Bernd Dörken in:

  18. Search for Johannes Zuber in:

  19. Search for Hinrich Gronemeyer in:

  20. Search for Michael Hummel in:

  21. Search for Gunnar Dittmar in:

  22. Search for Soyoung Lee in:

  23. Search for Clemens A. Schmitt in:


M.Mi. performed mouse lymphoma and leukaemia work, stem-cell and senescence assays, and gene set enrichment analyses. J.H.M.D. and M.R. conducted analyses with human cancer cell lines and primary human material. D.N.Y.F. and D.B. carried out flow cytometric analyses. Z.Z. generated leukaemias in the p53-regulatable mouse T-ALL model, I.A.M.B. and J.Z. in the p53-regulatable mouse AML model. Y.Y. carried out biochemical analyses. J.R.D. provided transcriptome analyses and long-term outcome data from senescence-capable mouse lymphomas. L.D. and M.A.M.-P. performed chromatin immunoprecipitations and analysed related datasets. D.L. conducted Affymetrix gene expression profiling and analyses. T.K. and G.D. carried out proteome analyses. M.Me. generated β-catenin/TCF-reporter cancer cell lines and performed luciferase reporter assays. K.P. generated qPCR data. A.T., B.D., H.G. and S.L. contributed to study design, data interpretation and preparation of the manuscript. M.H. provided immunohistochemical analyses. C.A.S. designed experiments, analysed the data and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Clemens A. Schmitt.

Reviewer Information Nature thanks J. P. Medema, J. Vormoor and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Life Sciences Reporting Summary

  2. 2.

    Supplementary Information

    This file contains patient information.

  3. 3.

    Supplementary Information

    This file contains supplementary data figure 1; showing the complete western blot membrane scans corresponding to extended data figures 2, 5, 6 and 8.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.